Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07578571 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
A Phase 1 study, sponsored by Immunome.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 175
- Enrollment target
NCT07578571: Recruiting Phase 1 study, sponsored by Immunome.
NCT07578571 is a Phase 1 study that is actively recruiting participants, run by Immunome. The registered enrollment target is 175 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (192% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07578571, a Phase 1 study, is actively recruiting participants, sponsored by Immunome.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 175 participants
- Enrollment target
Study Summary
This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.
Primary Outcome
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0
Interventions
- DRUG IM-1617
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2029-01 |
| Phase | Phase 1 |
What NCT07578571 shows while recruiting
NCT07578571 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (192% higher).
The record links to 0 conditions, and to 1 intervention - of which IM-1617 is the first listed.
NCT07578571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07578571 about?
NCT07578571 is a clinical study titled "A Phase 1 Study of IM-1617 in Participants With Advanced Cancer". This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test in...
What is the current status of trial NCT07578571?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2026-05-21. Estimated completion is 2029-01.
What interventions are being tested in trial NCT07578571?
The interventions under investigation include: IM-1617 (DRUG).
Who is sponsoring clinical trial NCT07578571?
This trial is sponsored by Immunome, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07578571's enrollment target sits among peer trials
175 319th of 2000 higher than 1,679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI